2,3,6-Trimethoxyamphetamine (2,3,6-TMA), also known as TMA-5, is a psychedelic drug and mild stimulant of the phenethylamine and amphetamine families. It is one of the possible positional isomers of trimethoxyamphetamine and is a positional isomer of 3,4,5-trimethoxyamphetamine (TMA or TMA-1).
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 2,3,6-TMA's dose as approximately 30mg or more orally and its duration as 8 to 10hours. Based on limited testing, the effects of 2,3,6-TMA were reported to include intense introspection, mild stimulation, and pupil dilation, among others. The drug was said to be comparable to about 75üg or more LSD. It is approximately 10times more potent than mescaline. However, it was noted that more testing was needed.
Unlike the other TMA isomers, 2,3,6-TMA was not tested at serotonin receptors or in rodent drug discrimination tests.
The chemical synthesis of 2,3,6-TMA has been described.
2,3,6-TMA was first described in the scientific literature by Alexander Shulgin in 1966. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
2,3,6-TMA is a controlled substance in Canada under phenethylamine blanket-ban language.
As a positional isomer of 3,4,5-trimethoxyamphetamine (TMA), 2,3,6-TMA is a Schedule I controlled substance in the United States.